Celldex Therapeutics reported $47.45M in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
AbbVie USD 6.57B 2.82B Jun/2026
Agenus USD 18.74M 16.26M Jun/2026
Amgen USD 13.99B 1.95B Jun/2026
Bristol-Myers Squibb USD 8.72B 852M Jun/2026
Celldex Therapeutics USD 47.45M 11.72M Jun/2026
Glaxosmithkline GBP 3.44B 146M Mar/2026
Nektar Therapeutics USD 149.58M 134.46M Mar/2026
Northwest Biotherapeutics USD 4.56M 244K Sep/2025
Pfizer USD 976M 727M Jun/2026
Rigel Pharmaceuticals USD 48.53M 4.87M Sep/2025
Roche Holding CHF 7.55B 579M Jun/2025